A5076498941- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Birth, Development, and Health
- Epigenetics and DNA Methylation
- HER2/EGFR in Cancer Research
- Single-cell and spatial transcriptomics
- Health, Environment, Cognitive Aging
- Bone health and treatments
- Prostate Cancer Treatment and Research
- Cinema History and Criticism
- Pluripotent Stem Cells Research
- Cancer, Hypoxia, and Metabolism
- Assisted Reproductive Technology and Twin Pregnancy
Virginia Commonwealth University
2022-2024
University of South Carolina
2022
Basal-like triple-negative breast cancer (TNBC) tumor cells are difficult to eliminate due resistance mechanisms that promote survival. While this subtype has low PIK3CA mutation rates when compared estrogen receptor-positive (ER+) cancers, most basal-like TNBCs have an overactive PI3K pathway gene amplification or high expression. BYL-719 is a inhibitor been found drug-drug interactions, which increases the likelihood it could be useful for combinatorial therapy. Alpelisib (BYL-719) with...
Abstract The goals of this study were to identify transcriptomic changes that arise in basal-like breast cancer cells during the development resistance epidermal growth factor receptor inhibitors (EGFRi) and drugs are cytotoxic once EGFRi occurs. Human patient-derived xenografts (PDXs) grown immunodeficient mice treated with a set EGFRi; erlotinib was selected for more expansive vivo studies. Single-cell RNA sequencing performed on mammary tumors from PDX WHIM2 vehicle or 9 weeks. then...
Abstract Breast cancer's complex transcriptional landscape requires a deep understanding of sample and cell diversity to identify effective treatments. In this study, we amalgamate single-cell RNA sequencing data from breast cancer patient-derived xenografts (PDX), organoids, lines, patient tumors reduction mammoplasties resulting in comprehensive dataset 117 samples with 506,719 total cells. These encompass hormone receptor positive (HR+), human epidermal growth factor 2 enriched (HER2E),...
Abstract Estrogen receptor (ER) signaling is the main driver of tumorigenesis in ER+ breast cancers by inducing proliferation and survival through genomic non-genomic means, therefore inhibition ER has been a mainstay treatment for decades. Roughly 30 percent patients will develop treatment-refractory recurrence or metastasis within their lifetime, which may include to bone, lung, liver, brain. Although advances approaches have prolonged average progression free survival, metastatic cancer...
Abstract Sacituzumab Govitecan (SG) is an antibody drug conjugate that targets the epithelial glycoprotein Trop-2. SG has been approved for treatment of patients with triple negative breast cancer (TNBC) or estrogen receptor positive (ER+) after they have received at least two previous systemic treatments. The objectives this study were to identify biomarkers response using patient-derived xenografts (PDXs) and determine if efficacy changes when cells become carboplatin resistant (CR)....
Abstract The inheritance of epigenetic marks induced by environmental variation in a previous generation is broadly accepted as mediator phenotypic plasticity. Transgenerational effects linking maternal experiences to changes morphology, gene expression, and life history successive generations are known across many taxa. While the number studies ecological increasing rapidly, few if any attempts have been made investigate molecular mechanisms governing functions context ecologically relevant...